Poster Session 3
Christina M. Scifres, MD (she/her/hers)
Professor
Indiana University School of Medicine
Indianapolis, Indiana, United States
Arunabh Sinha, BS
Indiana University School of Medicine
Indianapolis, Indiana, United States
Kaleab Abebe, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Christina Lalama, MS
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Tina Costacou, PhD
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Steve Orris, BS
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Patrick Catalano, MD
Professor
Tufts University
Tufts University/Boston, Massachusetts, United States
Esa Davis, MD
University of Maryland School of Medicine
Baltimore, Maryland, United States
Glucose intolerance in pregnancy is associated with long-term risk for type 2 diabetes (T2D). We evaluated metabolic characteristics and β-cell function during pregnancy and at 12 months postpartum among varying levels of glucose intolerance in pregnancy.
Study Design:
This is a planned follow-up to the Gestational Diabetes Diagnostic Methods (GDM2) trial, which randomized pregnant individuals to either a 75-gram oral glucose tolerance test (OGTT) with GDM diagnosed using the IADPSG criteria, or a 100g OGTT with GDM diagnosed by the Carpenter-Coustan (CC) criteria. All participants with treated GDM (diagnosed by either CC or IADPSG), those with untreated mild glucose intolerance (MGI, one abnormal value on CC criteria), and half of the participants with normal glucose tolerance were invited for a 75g OGTT at 12 months postpartum. Measures assessed at the time of GDM screening and at follow-up included metabolic characteristics, Stumvoll and Matsuda Indices to evaluate insulin sensitivity and resistance, and the Disposition Index (DI), which integrates insulin sensitivity and response.
Results:
Of the 407 individuals seen at 12 months, 49 (12%) had MGI and 53 (13%) had treated GDM (CC and IADPSG). MGI was associated with lower insulin sensitivity, lower beta cell function, dyslipidemia, and alterations in leptin and adiponectin similar to those individuals with treated GDM (Table). Measures of metabolic function, insulin sensitivity and β-cell function demonstrated similar rates of change from pregnancy to postpartum after adjusting for maternal age, BMI, and history of GDM.
Conclusion:
Patients with MGI have impaired β-cell function and significant metabolic abnormalities at 12 months postpartum similar to individuals with treated GDM and require ongoing follow-up for progression to T2D. The similar rate of change from pregnancy to postpartum in insulin sensitivity, β-cell function, and metabolic assessments among groups indicates that individuals were returning to their baseline levels of glucose tolerance rather than recovering from pregnancy-induced glucose intolerance.